We assessed agreement in haemoglobin measurement between Masimo pulse co-oximeters (Rad-7™ and Pronto-7™) and HemoCue® photometers (201+ or B-Hemoglobin) with laboratory-based determination and identified 39 relevant studies (2915 patients in Masimo group and 3084 patients in HemoCue group). In the Masimo group, the overall mean difference was -0.03 g/dl (95% prediction interval -0.30 to 0.23) and 95% limits of agreement -3.0 to 2.9 g/dl compared to 0.08 g/dl (95% prediction interval -0.04 to 0.20) and 95% limits of agreement -1.3 to 1.4 g/dl in the HemoCue group. Only B-Hemoglobin exhibited bias (0.53, 95% prediction interval 0.27 to 0.78). The overall standard deviation of difference was larger (1.42 g/dl versus 0.64 g/dl) for Masimo pulse co-oximeters compared to HemoCue photometers. Masimo devices and HemoCue 201+ both provide an unbiased, pooled estimate of laboratory haemoglobin. However, Masimo devices have lower precision and wider 95% limits of agreement than HemoCue devices. Clinicians should carefully consider these limits of agreement before basing transfusion or other clinical decisions on these point-of-care measurements alone.
The ability to rapidly and accurately determine the haemoglobin concentration of a patient can be useful or even critical in many clinical scenarios and this has resulted in the development of point-of-care (POC) devices aimed at meeting this goal. Current, non-invasive technologies include pulse co-oximetry (Pulse CO-Oximetry TM ; Masimo Corp., Irvine, CA, USA), occlusion spectroscopy (OrSense TM , Ness Ziona, Israel) and transcutaneous reflection spectroscopy (Haemospect, MBR Optical Systems, Herdecke, Germany) 1 . Invasive technologies (requiring a blood sample) include absorption photometry both reagent (HemoCue ® , HemoCue, Angelholm, Sweden) and nonreagent based (DiaSpect Haemoglobinometry, DiaSpect Medical GmbH, Germany) and conductivity based (i-Stat, Abbott Laboratories, Abbott Park, IL, USA) 2 . We focus here on Masimo pulse co-oximetry and HemoCue photometry. HemoCue devices are based upon invasive blood sampling (venous, capillary or arterial blood), where blood is loaded into a cuvette and undergoes chemical conversion to azide-haemoglobin with the concentration then measured by absorption photometry at two wavelengths (570 and 880 nm). These were first released in the mid-1980s and the technology (Hb 201+ system) improved in 2002 3 . Non-invasive transcutaneous pulse co-oximetry has been developed to measure total haemoglobin and its components (oxy, carboxy and met moieties) with one manufacturer, Masimo Corp., developing both continuous (Radical-7 TM ) and intermittent (Pronto-7 TM ) devices from 2008 3 . The two devices use different algorithms and only the continuous reading Radical-7 provides estimates of carboxy and methaemoglobin moieties 1 . This has led to the performance and publication of comparison studies to assess the accuracy of these POC technologies compared to laboratory-based methods, with the aim of determining if they provide a clinically useful substitute. It is important in these method comparison studies that both design and statistical analysis take account of the error in measurement of haemoglobin by both the established laboratory and the newer POC techniques. The two major statistical techniques used are the Bland-Altman agreement method 4,5 and linear mixed methods variance component modelling 6 .
We undertook a systematic review and meta-analysis with the aim of assessing the bias and precision of these two POC methods (HemoCue photometry and Masimo pulse co-oximetry) in determining total haemoglobin concentration from published method comparison studies.
Method
The literature search was limited to method comparison studies assessing agreement in haemoglobin determination between either Masimo Corp. pulse co-oximeters (continuous reading Radical-7 or intermittent Pronto-7) or HemoCue (Hb 201+, B-Hemoglobin systems) and laboratory-based determination. We performed an Ovid MEDLINE search (final search 20 May 2014) using MeSH terms-h(a)emoglobins, h(a)emoglobinometry, method comparison, point-of-care systems, oximetry-and keyword terms-non-invasive, continuous, co-oximetry, HemoCue, 201+, Masimo, Radical-7, Rad-7 and Pronto-7-published in English, in or after 1985 and performed on human subjects. Abstracts were not included and unpublished studies were not sought. We also searched reference lists of all accepted articles. Determination of each study's eligibility, performed independently by the authors, was initially based upon details presented in the abstract followed by full-text retrieval of all possible studies.
We defined the following eligibility criteria for studies to be included in this review. Exclusion criteria were 1) subjects aged less than two years old, 2) capillary-based sampling method (HemoCue device only), 3) data presented that did not allow extraction of summary measures (see later) and 4) where within-subject replicate sampling was performed, no adjustment for repeated measures had been performed. On the basis that, if within-subject replicates are treated as independent, then the estimation of difference standard deviation (SD diff ) is too small, resulting in falsely higher precision 5, 7 . If no such adjustment was made, then baseline data (first reading performed) was used where possible. All excluded articles and reason for exclusion are stated in the results. To assess the quality of included trials, we performed an analysis based upon the four risks of bias and three applicability concern domains found in the revised Quality Assessment of Diagnostic Studies (QUADRAS-2) guidelines 8 . Questions were tailored to method comparison outcomes (see Appendix 1 for questionnaire details). Data extraction was performed independently, with any disagreement referred to one of the authors for adjudication.
Study characteristics extracted for all studies were year of publication, number of subjects, age group of subjects (adult, child), laboratory haemoglobin minimum and maximum values (g/dl) and adjustment for within-subject replication. Laboratory-based methods used either chemical conversion of all haemoglobin moieties followed by absorption photometry, (classified as direct cyanomethaemoglobin analysis [HiCN], automated analysis using cyano/sodium lauryl sulphate haemoglobin conversion [eHiCN]) or absorption spectrophotometric analysis (co-oximetry) as used in standard blood gas analysers. Additional details recorded for Masimo pulse co-oximeters were software program and probe hardware versions and for HemoCue photometers model type (Hb 201+, B-Hemoglobin and unknown). The outcome details, in g/dl extracted, were mean haemoglobin difference (device versus laboratory) and SD diff . If mean difference (mean diff ) and SD diff were not presented in the text, then this was estimated from the difference against average graph or text using upper and lower 95% Limits of Agreement (LOA) where these were presented. The SD diff was then calculated from 95% LOA as (LOA upper -LOA lower )/3.92. For these individual studies, bias was assessed by the 95% confidence interval of the mean diff -1.96×SD diff ) and agreement by 95% LOA (mean diff -1.96×SD diff ).
Conceptually, individual studies constitute a random sample of all possible studies for each device (modelled using within device random effect) and we considered devices as fixed (modelled using between device fixed effect). Therefore, we performed mixed-effect (random effect within subgroup and fixed effect across subgroup) meta-analyses 9 for each method against the corresponding laboratory haemoglobin to provide pooled estimates of mean diff and SD diff as described by Williamson 10 . Pooled bias was then assessed by the 95% prediction intervals of the mean difference and pooled agreement by 95% LOA based upon the pooled SD. These prediction intervals are wider than pooled 95% confidence interval because they include an estimate of the true variability between studies under the random effects model 9 .
Between-study heterogeneity was identified using Q and I 2 statistics, both within subgroups and across all studies 9 
Results
Database and reference searches, after title and abstract assessment, identified 81 articles published between 1988 and 2010 for both HemoCue and Masimo devices. Fifty-two articles were obtained from the MEDLINE database and 28 from reference listings alone and one was our own paper. From these, 39 method comparison studies were identified as having met inclusion criteria after assessment of the full text article. Reasons for exclusion are presented in Table 1 . No adjustment for repeated measures 13 15, 18, 34, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] Subjects aged less than 2 years 5 53, [68] [69] [70] [71] Summary data (mean difference and SD of difference) not presented or extractable 11 [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] We found 24 studies (Table 2) , published from 2011 onwards, comparing Masimo pulse co-oximetry (18 Radical-7 continuous and 6 Pronto-7 intermittent) against co-oximetry (8), laboratory cyano/sodium lauryl sulphate haemoglobin conversion (14) and unspecified (2) . There were 19 studies (Table 3 ), based on venous or arterial blood samples, published from 1995 (12 from 2010) onwards, comparing HemoCue photometry devices (HemoCue Hb 201+ [6] , B-Hemoglobin [4] and unidentified [9] ) against co-oximetry (1) and laboratory cyano/sodium lauryl sulphate haemoglobin conversion (18) . Blood samples analysed were venous (14) or arterial (5) . Modified QUADRAS-2 analysis of included studies is presented in Table 4 .
In the Masimo group ( Table 2 and Figure 1 ), the number of subjects analysed was 2915, with 1516 (52%) using Radical-7 and 1399 (48%) using Pronto-7 devices. The overall pooled mean diff (device versus laboratory) was -0.03 g/dl (95% prediction interval -0.30 to 0.23), SD 1.42 g/dl and associated 95% LOA -3.0 to 2.9 g/dl ( Table 5 ). In the HemoCue group (Table 3 and Figure 2 ) the number of subjects analysed was 3084 with 669 (21.7%) using 201+, 1038 (33.7%) B-Hemoglobin and in 1377 (44.6%) the model was not identified. The overall pooled mean diff was 0.08 g/dl (95% prediction interval -0.04 to 0.20), SD 0.64 g/dl and associated pooled 95% LOA -1.3 to 1.4 g/dl (Table 5) .
Based upon overall pooled 95% prediction intervals for the mean diff , both methods provide unbiased pooled estimates of laboratory haemoglobin. However, the B-Hemoglobin device exhibits fixed bias with a pooled mean diff of 0.53 g/dl (95% prediction interval 0.27 to 0.78). Precision is more than two times higher (SD diff smaller) for HemoCue compared to Masimo technologies. These differences directly translate to the wider pooled 95% LOA for Masimo devices, both overall and within subgroups ( Table 5 ). Heterogeneity in summary estimates, both overall and between subgroups for the HemoCue and Masimo models, based upon the Q-statistic and associated P-values are presented in Table 5 . Subgrouping by model removed heterogeneity only for the HemoCue 201+ device. The I 2 statistic indicates a moderate level of heterogeneity within the HemoCue 201+ subgroup but marked heterogeneity for all other comparisons. 25, 30, 35, 36, 42, 56 No light shield 36, 42 
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Calibration not stated 38, 39, 43, 87 no explicit statement that manufacturers's guidelines followed 16 1. Patient selection. Is there concern that the included patients do not match the review question?
All Nil Nil All Nil Nil 2. Index test. Is there concern that the index test, its conduct or interpretation differ from review question?
1 No reference to signal quality being adequate [34] [35] [36] 42, 56 Nil All Nil Nil 3. Reference standard. Is there concern that the target condition as defined by the reference standard does not match the review question? 
Discussion
Haemoglobin measurement is an important determinant of when and how much to transfuse. The use of POC devices requires the clinician to balance the speed and ease of rapid analysis versus the accuracy of traditional laboratory methods. A large number of studies have been performed that attempt to ascertain whether either the HemoCue or Masimo POC devices provide useful haemoglobin estimation at the bedside or in the clinic. When interpreting whether either device meets this goal, it is important to view individual study results along with evidence from other method comparison studies.
Our results indicate that both Masimo co-oximeters (Rad-7 and Pronto-7) provide unbiased pooled estimates of the laboratory haemoglobin, with the 95% prediction intervals of mean diff covering zero difference ( Table 5 ). Of the identified HemoCue devices, the 201+ provides an unbiased pooled estimate of mean diff whilst the B-Hemoglobin model has a fixed bias, overestimating laboratory haemoglobin with a 95% prediction interval of 0.27 to 0.78 g/dl.
To use POC devices in place of laboratory haemoglobin estimates requires that the 95% LOA are narrow enough to provide clinically useful assessment of laboratory haemoglobin concentration.
For Masimo devices, both within subgroup and overall, 95% LOA are wide, approximately ±3 g/dl while substantially narrower limits were found for HemoCue devices (±2 g/dl).
In a recently published systematic review and metaanalysis assessing agreement of pulse co-oximeters, Masimo (Radical-7 and Pronto-7) and OrSense (NBM-200 TM , OrSense Ltd, Ness Ziona, Israel) devices, Kim et al 11 found a pooled mean bias (pooled SD devices) of -0.02 g/dl (1.42) and 0.05 g/dl (1.23) for Radical-7 and Pronto-7 devices respectively with differences in included studies reviews accounting for the small differences in bias and precision estimates. For HemoCue devices these authors provide a single estimate (1.6 g/dl) for the SD of mean diff based upon three studies [12] [13] [14] that was substantially larger than our pooled estimate of 0.64 g/dl based on 19 studies.
For both technologies, unexplained variability accounts for most (I 2 >90%) of the variability within models, the exception being the HemoCue 201+, where only moderate levels were found (I 2 =47.4%). Potential sources of variability using the Masimo devices include size and type of sensor and sensor application 1 . However, due to the larger number of software and hardware revisions, we were unable to perform a sensitivity analysis. QUADRAS-2 analysis found only three studies where manufacturers' recommendations regarding sensor placement and shielding were not followed and it is unlikely that this substantially contributes to the heterogeneity found. For the HemoCue devices, potential sources of variability include the quality of the cuvette reagents (due to storage deterioration) and incomplete loading of the cuvette 15 ; 12/19 studies recorded compliance with the relevant manufacturer's storage and all met handling guidelines. The HemoCue 201+ is self-calibrating, whilst the B-system requires daily manual calibration, and in only four studies, all using unknown models, was compliance with this requirement not explicitly stated (see Table 4 ).
Many practitioners use capillary blood samples to obtain specimens for HemoCue testing. HemoCue estimation using capillary blood may differ from that using venous samples, due,either to real differences in haemoglobin concentration between the two sites, or errors introduced by capillary sampling. When assessed by laboratory analysers, capillary haemoglobin is, on average, higher than in venous blood. Neufeld 16 , using a calibrated laboratory analyser, found the mean haemoglobin estimated from capillary samples 0.42 g/dl (SD 0.45) higher than venous blood. Errors in sampling technique can contribute to increased variability 17 , with Chen 18 showing increased within-subject variability in HemoCue haemoglobin estimation when using capillary (coefficient of variation 8%) compared to venous (coefficient of variation 2%) blood. When using the 201+ device, using the mean of three replicate readings did not meaningfully increase precision compared to a single reading although, it does allow for detection of aberrant readings 19 . In this meta-analysis we included only studies using venous or arterial blood, excluding capillary sampling as a source of variability. Limitations of this systematic review include the restriction of studies to those published in English and our requirement that outcome data must be presented as difference and SD of difference and not estimated from independent grouped data. These restrictions may have limited the number of studies included in this review; however, it seems unlikely that summary estimates would be systematically different to bias results.
Conclusion
We conclude that both Masimo devices and the HemoCue 201+ provide unbiased estimates of laboratory haemoglobin, with a small positive bias found for the B-Hemoglobin device. Masimo devices have lower precision and wider 95% LOA than HemoCue devices. These LOA provide guidance for clinicians in interpreting haemoglobin estimates from these devices. Clinicians should carefully consider these LOA before basing transfusion or other clinical decisions on these POC measurements alone.
